eptifibatid mylan solution for injection 2mg ml - תוצאות חיפוש

ארצות הברית - אנגלית - NLM (National Library of Medicine)

eptifibatide injection, solution

usv private limited - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies (14.1, 14.2)] . treatment with eptifibatide injection is contraindicated in patients with: - a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days - severe hypertension (systolic blood pressure >200 mm hg or diastolic blood pressure >110 mm hg) not adequately controlled on antihypertensive therapy - major surgery within the preceding 6 weeks - history of stroke within 30 days or any history of hemorrhagic stroke

ישראל - אנגלית - Ministry of Health

eptifibatide medi-market 0.75 mgml

a.l. medi-market ltd. - eptifibatide - solution for infusion - eptifibatide 0.75 mg / 1 ml - eptifibatide - eptifibatide medi-market is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide medi-market is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide medi-market is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). eptifibatide medi-market is intended for use with aspirin and heparin.

ישראל - אנגלית - Ministry of Health

eptifibatide medi-market 2 mgml

a.l. medi-market ltd. - eptifibatide - solution for injection - eptifibatide 2 mg / 1 ml - eptifibatide - eptifibatide medi-market is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide medi-market is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide medi-market is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). eptifibatide medi-market is intended for use with aspirin and heparin.